Vast

Vast Therapeutics is a clinical-stage life science company dedicated to developing transformative, nitric oxide-based therapies for patients with chronic and severe respiratory diseases. The company's proprietary platform utilizes water-soluble, small molecule prodrugs and biopolymers designed to deliver controlled, sustained-release nitric oxide directly to the lungs via inhalation. This dual-action approach provides both potent antimicrobial activity against multi-drug resistant pathogens (such as Pseudomonas aeruginosa and Nontuberculous mycobacteria) and critical anti-inflammatory effects by targeting the NLRP3 inflammasome. Vast's lead candidate, ALX1, is currently in Phase 2 clinical development for bronchiectasis, with additional programs targeting cystic fibrosis and chronic obstructive pulmonary disease (COPD).